Lung Cancer
News
Neoadjuvant-adjuvant erlotinib shows promise in locally advanced NSCLC
The EMERGING trial failed to meet its primary endpoint of higher OR but did meet the secondary endpoint of longer PFS.
Conference Coverage
Adding ipilimumab to nivolumab provides no benefit in SCC trial
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
News
FDA approves NovoTTF-100L System for advanced mesothelioma
The System delivers electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division and can be prescribed only by a...
News
Local consolidative therapy shows benefit in oligometastatic NSCLC
Patients treated with local consolidative therapy had a median overall survival of 41.2 months, compared with 17.0 months among patients treated...
News
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?
One common EGFR tyrosine kinase inhibitor–sensitizing allele may be associated with similar benefit versus EGFR wild-type lung tumors, analysis...
Conference Coverage
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Pooled KEYNOTE data support pembro for elderly patients with NSCLC
GENEVA – Investigators analyzed data from 264 patients 75 years or older involved in the KEYNOTE-010, KEYNOTE-024,...
Conference Coverage
Tumor-treating fields boost chemo for mesothelioma
GENEVA - Patients with malignant pleural mesothelioma who were treated with TTFields in combination with pemetrexed and...